SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is currently facing significant volatility as investors brace for the upcoming FDA Advisory Committee meeting to evaluate the clinical efficacy of its DMD therapy. The community is sharply divided, with bulls pointing to robust Phase 3 data and strong support from the patient advocacy community, while bears are citing regulatory skepticism, insider selling, and potential patent litigation as major headwinds.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following an agreement to expand its use of quantum computing technology across AT&T's network operations, a move aimed at enhancing optimization and network efficiency. While the stock has seen volatility as part of a broader macro-driven unwind in high-beta tech, the community is actively debating the company's long-term enterprise traction and valuation against its upcoming quarterly earnings report.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing a significant surge in investor attention following the appointment of Michael Severino as its new CEO, a move the community views as a critical step toward restoring corporate credibility. Discussion is further amplified by market activity surrounding Capricor Therapeutics, with investors viewing the developments at both firms as potential catalysts for a bullish shift in sentiment as they head toward the next earnings update.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros shares are trending as investors weigh potential market competition following an AstraZeneca trial result while looking ahead to key milestones like CMS reimbursement updates and EMA re-examination. The community is actively debating the significance of recent Symphony prescription data and its impact on the company's valuation versus long-term growth prospects.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is attracting intense investor attention following new executive orders aimed at accelerating U.S. quantum technology leadership and security infrastructure. While the community is actively debating the stock's long-term potential versus concerns over high valuations and insider selling, traders are closely monitoring how these government-linked catalysts will impact near-term momentum.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently the subject of intense retail speculation and volatility as investors debate the impact of upcoming share lock-up expirations against the company's long-term aerospace and AI infrastructure ambitions. Community sentiment remains sharply divided between bulls focused on successful flight milestones and long-term tech integration, and skeptics who are concerned about excessive valuation and potential selling pressure from institutional insiders.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is trending as it enters a definitive agreement to be acquired by Argenx in an all-cash transaction. The community is actively discussing the deal, with many noting the significant premium and the stock trading tightly aligned with the acquisition price as market participants treat the buyout as a finalized event.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is trending as investors monitor the company's efforts to secure a third attempt at FDA approval for RP1, following an alignment with the agency on a resubmission path. The community remains sharply divided, with intense debate over the reliability of existing clinical data, the company's financial runway, and the potential impact of recent leadership shifts within the FDA.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

ProShares Ultra Bloomberg Crude Oil is experiencing significant volatility driven by shifting geopolitical tensions and ongoing diplomatic efforts to address stability in the Middle East. The community is actively debating the potential impacts of a possible ceasefire versus the structural realities of oil supply, with many traders closely monitoring how these headlines influence the leveraged performance of the fund.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is currently drawing significant investor attention due to active discussions regarding potential re-listing news and the company's aggressive expansion efforts in the U.S. market. Community sentiment remains polarized, with many investors debating the company's growth-versus-profitability narrative ahead of upcoming earnings, while others remain focused on the potential impact of share buybacks and long-term valuation recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$1000 Invested In Vanguard Russell 1000 Growth ETF 15 Years Ago Would Be Worth This Much Today

Vanguard Russell 1000 Growth ETF (NASDAQ:VONG) has outperformed the market over the past 15 years by 2.57% on an annualized basis producing an average annual return of 14.9%. Currently, Vanguard Russell 1000 Growth ETFread more...

Meet the Growth ETF That's Turned $1,000 Into $5,400 Over 10 Years. History Says the Next Decade Could Be Even Better.

Key PointsThe Vanguard Russell 1000 Growth ETF (VONG) targets the broader large-cap universe for stocks with faster-growing revenues and earnings...

Should Vanguard Russell 1000 Growth Index Fund ETF Shares (VONG) Be on Your Investing Radar?

Vanguard Russell 1000 Growth ETF vs SPDR S&P 600 Small Cap Growth: Which Fund Is the Better Buy?

Key PointsVanguard Russell 1000 Growth ETF features a significantly lower expense ratio of 0.06% compared to the 0.15% fee for State Street SPDR S&P 600 Small Cap Growth ETF...

$100 Invested In Vanguard Russell 1000 Growth ETF 10 Years Ago Would Be Worth This Much Today

Vanguard Russell 1000 Growth ETF (NASDAQ:VONG) has outperformed the market over the past 10 years by 3.69% on an annualized basis producing an average annual return of 17.22%. Currently, Vanguard Russell 1000 Growth ETFread more...

VOOG vs. VONG: Which Vanguard Growth ETF Is the Better Buy?

Key PointsBoth the Vanguard S&P 500 Growth ETF (VOOG) and the Vanguard Russell 1000 Growth ETF (VONG) have low expense ratios of 0.07% and 0.06%, respectively...

Which Is the Better Growth ETF, Vanguard's Russell 1000-Focused VONG or Invesco's Small-Cap RZG?

Key PointsThe Vanguard Russell 1000 Growth ETF offers a significantly lower expense ratio of 0.06% than the 0.35% charged by the Invesco S&P SmallCap 600 Pure Growth ETF...

Vanguard's VONG or iShares' IJT: Which Growth ETF Should Long-Term Investors Choose?

Key PointsVanguard Russell 1000 Growth ETF provides a lower cost structure than iShares S&P Small-Cap 600 Growth ETF...

Vanguard ETF Showdown: Is The Fund Giant's Growth ETF or Russell 1000 Growth ETF Better?

Key PointsVanguard Growth ETF and Vanguard Russell 1000 Growth ETF both offer extremely low-cost access to U.S. large-cap growth stocks...

Which Is the Better Growth-Focused ETF, Vanguard's Large-Cap VONG or State Street's Small-Cap SLYG?

Key PointsThe Vanguard Russell 1000 Growth ETF focuses on large-cap leaders like Nvidia while the State Street SPDR S&P 600 Small Cap Growth ETF targets smaller high-momentum companies...

Vanguard Scottsdale Funds - Vanguard Russell 1000 Growth Index ETF

ONON Stock Falls After Surprise CEO Resignation Leaves Wall Street Divided

Equity

Bullish Sentiment

U.S. - Iran negotiations

Earnings

FOMC meeting

Other (drop a comment)

This week brings a Federal Reserve rate decision, Q2 GDP and PCE inflation data, and earnings from $MSFT, $META, $AAPL, and $AMZN. What will be the biggest driver of the market this week? Vote and explain your reasoning in the comments.

What will be the main driver of the market this week? 
 
Explain your reasoning in the comments.

Feed

News

Sentiment

Fundamentals

Info

VONGVanguard Russell 1000 Growth Index ETF

Fundamentals

Latest VONG News